Alkermes (ALKS) 10-Q2024 Q1 Quarterly report

Filed: 1 May 24, 5:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: advice, affirming, ASC, assumption, ASU, category, classification, component, composition, description, disciplined, distribution, employment, extend, fail, feet, field, flat, guarantor, Guaranty, human, instructed, jurisdictional, multinational, mutual, nominal, Nordisk, Novo, order, Organization, original, par, pediatric, permitted, perpetual, pillar, prejudice, President, prioritization, prospective, public, purpose, question, ratified, recast, reconcile, reform, remanding, removal, remove, retrospective, retrospectively, rounding, Senior, space, square, stability, statement, Street, subcontracting, sublicense, sum, suspended, tenant, tied, title, Topic, transparency, upward, vacating, Vice, Winter

Removed: acknowledged, administration, advanced, advancing, advisor, affinity, AG, alfa, alpha, ANJESO, announcement, ARTISTRY, avoiding, aware, Baudax, began, Bio, Book, CABENUVA, cancer, capitalization, care, chain, chemotherapy, choice, Cilag, Code, collateral, collect, commercially, complex, comprised, conducted, Conflict, conserve, consideration, CONSTA, consummated, continuation, CPR, derive, design, designation, discontinuation, discontinue, discovery, discretion, division, Dohme, Dublin, efficacy, ending, engineered, enhanced, enter, equal, expertise, expire, expired, explore, fact, Fast, Food, foreign, fusion, GA, Gainesville, growth, headcount, ILAP, immune, immunosuppressive, immunotherapy, impacted, impaired, inclusive, inherent, inherently, Innovation, Institute, investigator, KEYTRUDA, Kingdom, launch, launched, listing, manner, melanoma, Meloxicam, MHRA, milestone, mitigating, mucosal, negatively, negotiated, nemvaleukin, notwithstanding, occurred, open, operation, Orange, Orphan, ovarian, pandemic, parenteral, Passport, past, Pathway, pay, pembrolizumab, point, preferentially, prevent, privately, projected, proportion, protein, proven, Recro, reduce, rely, RISPERDAL, risperidone, SC, scientific, selectively, selectivity, settle, Sharp, shipment, significantly, SOFR, solid, spun, strategic, supply, tracking, turn, UK, unpredictable, vary, varying, Wilmington, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ALKS transcripts

ALKS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Alkermes plc (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Richard F. Pops, Chairman and Chief Executive Officer of the Company, and Blair C. Jackson, Executive Vice President, Chief Operating Officer and Interim Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	Date: May 1, 2024		/s/ Richard F. Pops
			Richard F. Pops

			Chairman and Chief Executive Officer
			(Principal Executive Officer)


	Date: May 1, 2024		/s/ Blair C. Jackson
			Blair C. Jackson

			Executive Vice President, Chief Operating Officer
			(Interim Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.